CMRX vs. FBIO, SCPH, CHMA, NATR, AQST, ALXO, ACB, STRO, ENTA, and AVIR
Should you be buying Chimerix stock or one of its competitors? The main competitors of Chimerix include Fortress Biotech (FBIO), scPharmaceuticals (SCPH), Chiasma (CHMA), Nature's Sunshine Products (NATR), Aquestive Therapeutics (AQST), ALX Oncology (ALXO), Aurora Cannabis (ACB), Sutro Biopharma (STRO), Enanta Pharmaceuticals (ENTA), and Atea Pharmaceuticals (AVIR). These companies are all part of the "medical" sector.
Fortress Biotech (NASDAQ:FBIO) and Chimerix (NASDAQ:CMRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.
Fortress Biotech has a beta of 1.74, indicating that its share price is 74% more volatile than the S&P 500. Comparatively, Chimerix has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.
Fortress Biotech currently has a consensus price target of $28.50, indicating a potential upside of 1,026.48%. Chimerix has a consensus price target of $8.50, indicating a potential upside of 855.06%. Given Chimerix's higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Chimerix.
Chimerix received 60 more outperform votes than Fortress Biotech when rated by MarketBeat users. However, 63.92% of users gave Fortress Biotech an outperform vote while only 63.59% of users gave Chimerix an outperform vote.
96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 45.4% of Chimerix shares are held by institutional investors. 33.4% of Fortress Biotech shares are held by company insiders. Comparatively, 13.1% of Chimerix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Fortress Biotech has higher revenue and earnings than Chimerix. Chimerix is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.
In the previous week, Fortress Biotech had 6 more articles in the media than Chimerix. MarketBeat recorded 8 mentions for Fortress Biotech and 2 mentions for Chimerix. Fortress Biotech's average media sentiment score of 1.10 beat Chimerix's score of 0.38 indicating that Chimerix is being referred to more favorably in the news media.
Fortress Biotech has a net margin of -69.13% compared to Fortress Biotech's net margin of -25,337.96%. Chimerix's return on equity of 0.00% beat Fortress Biotech's return on equity.
Summary
Fortress Biotech beats Chimerix on 13 of the 17 factors compared between the two stocks.
Get Chimerix News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chimerix Competitors List
Related Companies and Tools
